This site is intended for healthcare professionals outside the US

×

SANDOSTATIN® LAR® PROVIDES SYMPTOM CONTROL FROM THE FIRST DOSE

Print |
Sandostatin® LAR® provides continuous control of symptoms associated with functional gastroenteropancreatic (GEP) endocrine tumors (eg, carcinoid tumors with features of the carcinoid syndrome).1

Sandostatin® LAR® suppresses 5-HIAA levels for effective management of symptoms2,3

In functioning neuroendocrine tumors (NET), bioactive secretions from NET elevate 5-hydroxyindoleacetic acid (5-HIAA) levels, leading to the manifestation of symptoms including severe diarrhea and flushing. Sandostatin® LAR® has been shown to reduce 5-HIAA levels by up to 50%.2-4

Control of flushing and diarrhea symptoms: In functional GEP endocrine tumors

The control of flushing and diarrhea begins with the first dose of Sandostatin® LAR®.2,3

Flushing

The control of flushing and diarrhea begins with the first dose of Sandostatin® LAR®

Diarrhea

The control of flushing and diarrhea begins with the first dose of Sandostatin® LAR®

Sandostatin® LAR® provides continuous symptom control.1

Sandostatin® LAR® reduces diarrhea and flushing2,3

Reduction in 84% reduction in flushing frequency and an diarrhea frequency of 42%

Study details: A 6-month randomized trial compared double-blinded Sandostatin® LAR® at 10, 20, and 30 mg every 4 weeks with open-label Immediate-release Sandostatin® Injection every 8 hours for the treatment of carcinoid syndrome (N=93).2,3
It is recommended to start treatment with the administration of 20 mg Sandostatin® LAR® at 4-week intervals. Patients on treatment with s.c. Sandostatin® should continue at the previously effective dosage for 2 weeks after the first injection of Sandostatin® LAR®.1
For patients in whom symptoms and biological markers are well controlled after 3 months of treatment, the dose may be reduced to 10 mg Sandostatin® LAR® every 4 weeks.1
For patients in whom symptoms are only partially controlled after 3 months of treatment, the dose may be increased to 30 mg Sandostatin® LAR® every 4 weeks.1

References:
1. Sandostatin® LAR® Summary of Product Characteristics. Novartis Pharma AG. 2018. 2. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606. 3. Sandostatin® LAR® Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019. 4. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:1559-1574.